SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- obesity/erectile dysfunction
An SI Board Since February 2001
Posts SubjectMarks Bans
435 30 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
360Mol Pharmacol. 2015 Apr 22. pii: mol.115.098483. [Epub ahead of print] CB1 Knocscaram(o)uche-5/22/2015
359Life Sci. 2015 Apr 25. pii: S0024-3205(15)00220-9. doi: 10.1016/j.lfs.2015.04.00scaram(o)uche-5/21/2015
358Biol Psychiatry. 2015 Apr 14. pii: S0006-3223(15)00314-5. doi: 10.1016/j.biopsycscaram(o)uche-5/21/2015
357Neurosci Lett. 2015 Apr 14. pii: S0304-3940(15)00297-9. doi: 10.1016/j.neulet.20scaram(o)uche-4/20/2015
356If you want the benefits of medical marijuana without the "unwanted side efDoc Bones-4/11/2015
355Neurosci Lett. 2015 Apr 3. pii: S0304-3940(15)00273-6. doi: 10.1016/j.neulet.201scaram(o)uche-4/9/2015
354J Neurosci. 2015 Mar 4;35(9):3879-3892. Corticotropin-Releasing Hormone Drives scaram(o)uche-3/6/2015
353Proc Natl Acad Sci U S A. 2014 Dec 22. pii: 201421420. [Epub ahead of print] A scaram(o)uche-12/28/2014
352Arthritis Res Ther. 2014 Sep 27;16(5):437. [Epub ahead of print] Tapping into tscaram(o)uche-9/30/2014
351Front Neurol. 2014 Aug 28;5:161. doi: 10.3389/fneur.2014.00161. eCollection 2014scaram(o)uche-9/17/2014
350Proc Natl Acad Sci U S A. 2014 Jun 3. pii: 201406728. [Epub ahead of print] Thescaram(o)uche-6/14/2014
349>> Efficacy is not an issue. In phase III testing, toxicity will be a big scaram(o)uche-4/22/2014
348More Evidence Supports Obesity Drug Entering Clinical Trials Fri, 12/20/2013 - 1tnsaf-1/2/2014
347Thanks! Efficacy is not an issue. In phase III testing, toxicity will be a bigscaram(o)uche-11/15/2013
346Zafgen's P2 for it's MetAP2 inhibitor beloranib seems to have gone quitetuck-11/15/2013
345Fighting Obesity With Gut Bacteria Sep 11, 2013NEW YORK (Reuters Health) Sep 11russet-9/17/2013
344Brain Res. 2013 Sep 7. pii: S0006-8993(13)01169-4. doi: 10.1016/j.brainres.2013.scaram(o)uche-9/17/2013
343Br J Pharmacol. 2013 Aug 28. doi: 10.1111/bph.12360. [Epub ahead of print] Ananscaram(o)uche-9/4/2013
342FASEB J. 2013 Aug 27. [Epub ahead of print] The CB1 receptor mediates the peripscaram(o)uche-8/29/2013
341So, let's see.... aspirin, ibuprofen, etc. And through a different routescaram(o)uche-8/28/2013
340nature.com Nature Neuroscience 16, 1291–1298 (2013) doi:10.1038/nn.3480 Receivscaram(o)uche-8/28/2013
339>> even includes at least one CB1R antagonist << er......... wellscaram(o)uche-8/3/2013
338Between the lines, these investigators are saying that mixtures of phytocannabinscaram(o)uche-7/30/2013
337Neuropsychopharmacology. 2013 Jun 24. doi: 10.1038/npp.2013.153. [Epub ahead of scaram(o)uche-6/27/2013
336(emphasis mine, and it never did make sense that curcumin would both exhibit antscaram(o)uche-4/13/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News